Topics

The results demonstrated that patients who were taking drugs to speed up the breakdown of fats in their lungs were recovering from lung infections caused by COVID-19 in a matter of days—with no mortality among these patients.

Guardant Reveal, is a plasma-only ctDNA test for detection of early-stage colorectal cancer, with additional cancer types to follow. The minimal residue disease test, which will have a turnaround time of seven days, had been in development since 2016 under the name LUNAR-1, and was launched for research use only in 2019.

Moderna said its vaccine candidate produced neutralizing antibodies in older and elderly adults, while Regeneron said REGN-COV2 rapidly reduced viral load as well as time to alleviate symptoms in non-hospitalized patients.

Dubbed TriSilix, the chip performs a miniature version of polymerase chain reaction (PCR) testing on bodily fluids, feces, or environmental samples, according to the scientists at Imperial College London who developed the new technology.

In studies of a group of 171 heart transplant recipients, the new blood test performed better than tissue biopsies, signaling problems even when no outward signs of rejection were evident.

Leveraging both Sanger sequencing and long-read technology , PacBio and Invitae will look to develop new whole-genome assays in areas such as carrier screening, immune system response, and other heritable diseases.

SARS-CoV-2 can affect many other organs in the body including the central nervous system, where the infection is associated with a variety of symptoms ranging from headaches and loss of taste and smell to impaired consciousness, delirium, strokes, and cerebral hemorrhage.

The study shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection.

A big advantage of the new sensor is that it only requires a very small amount of blood—around 5 microliters—to work. It can also detect levels of antibodies as low as 0.15 nanograms per milliliter.

About half of the patients who were very sick with COVID-19 were exhibiting a combination of high levels of both the dangerous antibodies and super-activated neutrophils, which are destructive, exploding white blood cells.